This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Comparison of Saquinavir Hard- and Soft-Gelatin Capsules in HIV-Infected Patients

This study has been completed.
Information provided by:
NIH AIDS Clinical Trials Information Service Identifier:
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: July 1997
To compare the antiviral activity, safety, and pharmacokinetics of saquinavir hard gel capsule (HGC) formulation, to 1 of 3 doses of saquinavir soft gel capsule (SGC) formulation administered orally every 8 hours for 4 weeks.

Condition Intervention Phase
HIV Infections Drug: Saquinavir Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: A Randomized, Parallel, Open-Label Study Comparing Saquinavir (Hard Gelatin Formulation, 600 Mg Tid) to Saquinavir Soft Gelatin Formulation [(400 Mg, 800 Mg, 1200 Mg) Tid} x 4 Weeks in HIV Infected Patients

Resource links provided by NLM:

Further study details as provided by NIH AIDS Clinical Trials Information Service:

Estimated Enrollment: 80
Detailed Description:

Patients are randomly assigned to one of the four treatment groups as follows:

Group 1: 10 patients receive saquinavir HGC. Group 2: 10 patients receive saquinavir SGC. Group 3: 30 patients receive saquinavir SGC at an intermediate dose. Group 4: 30 patients receive saquinavir SGC at the highest study dose. Upon completion of the initial 4 weeks, all patients may have the option to continue their originally-assigned therapy as monotherapy unless significant drug toxicity intervenes. If the analysis of the initial 4 week data identifies an optimal dose of saquinavir SGC, patients may have the option to change to this optimal dose in a treatment extension phase of the protocol. Patients in this extension phase may choose to remain on monotherapy unless they experience significant drug toxicity, their CD4 count or HIV-RNA levels return to baseline, until saquinavir is approved by the FDA or study termination, whichever comes first.

NOTE: A washout >= 28 days is required for patients on antiretroviral therapy.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

Patients must have:

  • CD4 count of 100 to 500 cells/mm3.
  • Greater than 20,000 HIV-RNA copies/ml.

Exclusion Criteria

Prior Medication:


Prior treatment with protease inhibitors.


  • Less than 8 weeks prior antiretroviral treatment (For at least 25% of patients).
  • At least 8 weeks prior antiretroviral treatment (For at least 25% of patients).
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00002383

United States, Alabama
Univ of Alabama at Birmingham / 1917 Rsch Cln
Birmingham, Alabama, United States, 35294
United States, California
Davis Med Ctr
San Francisco, California, United States, 94114
Mt Zion Hosp of UCSF / HIV Research Ctr
San Francisco, California, United States, 94115
Pacific Oaks Med Group / Research & Scientific Investiga
Sherman Oaks, California, United States, 91403
United States, Louisiana
Tulane Univ Med Ctr / Infectious Diseases Sect
New Orleans, Louisiana, United States, 70112
United States, Massachusetts
New England Med Ctr
Boston, Massachusetts, United States, 02111
United States, Missouri
Kansas City AIDS Research Consortium
Kansas City, Missouri, United States, 64108
United States, New York
Harkness Pavilion
New York, New York, United States, 10032
United States, Oregon
Oregon Health Sciences Univ
Portland, Oregon, United States, 97201
United States, Texas
Univ of Texas Med Branch / Virology Clinic
Galveston, Texas, United States, 775550882
Sponsors and Collaborators
Hoffmann-La Roche
  More Information

Publications: Identifier: NCT00002383     History of Changes
Other Study ID Numbers: 229M
Study First Received: November 2, 1999
Last Updated: June 23, 2005

Keywords provided by NIH AIDS Clinical Trials Information Service:
Drug Administration Schedule
HIV Protease Inhibitors
Dosage Forms
Anti-HIV Agents

Additional relevant MeSH terms:
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors processed this record on August 23, 2017